Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Avenue Therapeutics Q3 2026 Results: Net Loss of $691K, Loss Widens

Avenue Therapeutics reported a net loss of $2.1 million for the nine months ended September 30, 2026, compared to $2.2 million in the prior year period. The company currently generates no revenue and has expressed substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $107.6 million and limited cash reserves of $1.5 million.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-0.7-0.7
EPS (diluted, $ a share)$-0.20$-0.21

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: ATXI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Avenue Therapeutics, Inc.: key numbers

Share price
$0.2570Close, Nov 16
Market cap
$847K
Shares outstanding
3.29MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.